Application of AMACR combined with P63 or CK34βE12 in diagnosis and differentiation of prostate adenocarcinoma

Objective To evaluate the application of AMACR combined with P63 or CK34βE12 in diagnosis and differentiation of prostate adenocarcinoma. Methods AMACR, P63 and CK34βE12 immunohistochemistry were applied in 73 cases of prostatic adenocarcinoma(PC) ,high-grade prostatic intraepithlial neoplasia(HGPIN) , low-grade prostatic intraepithlial neoplasia(LGPIN) , atypical adenomatous (AAH) and benign prostatic hyper plasia (BPH). Results ①27 of the 28(96. 43%) cases of PC and10 of the 12 (83. 33%) cases of HGPIN stained positive for AMACR, with strong staining in most cases. In LGPIN (11.11% ,1/9) , AAH(16.7% ,1/ 6) , and BPH(0) ,the positive expression rates were significantly lower than that of PC(P0. 001). However, there was no significant difference between PC and HGPIN(P = 0.209) . ② All 28 carcinoma cases showed negative for P63 or CK34βE12 and BPH, AAH, LGPIN showed positive for P63 or CK34βE12 too. Expression of P63 or CK34βE12 was demonstrated in HGPIN at frequencies of 10/12(83.33%) and 11/12(91.67%), respectively. There was significant difference in P63 or CK34βE12 expression between PC and HGPIN, LGPIN, AAH,BPH(P0.001). ㏕he AMACR positive expression combined with the P63 or CK34βE12 negative expression was demonstrated in PC at the rate of 96.43% , HGPIN, 8.33% . All of BPH, AAH, LPIN showed negative for AMACR combined with P63 or CK34βE12. Conclusion AMACR is a useful tumor marker for diagnosis of prostatic adenocarcinoma. The application of AMACR combined with P63 or CK34βE12 may be of greater benefit in diagnosing and differentiating prostate adenocarcinoma.